2. Search Result
Search Result
Results for "

C57BL/6B mice

" in MedChemExpress (MCE) Product Catalog:

2734

Inhibitors & Agonists

1

Screening Libraries

19

Fluorescent Dye

30

Biochemical Assay Reagents

194

Peptides

1

MCE Kits

93

Inhibitory Antibodies

415

Natural
Products

23

Recombinant Proteins

79

Isotope-Labeled Compounds

21

Antibodies

12

Click Chemistry

68

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W110925
    Alkali blue 6B monosodium(IND)

    		Biochemical Assay Reagents Others
    Alkali blue 6B monosodium (IND) is a basic dye that can be used as a reagent in biochemical and medical research. Alkali blue 6B monosodium (IND) interacts with various proteins, and can be used in protein adsorption studies. Alkali blue 6B monosodium (IND) contains SO3H -, NH and OH groups that may react with divalent heavy metal ions, and can be used for the removal of heavy metals from aqua .
    Alkali blue 6B monosodium(IND)
  • HY-D0939
    Direct Blue 1
    1 Publications Verification

    Chicago Sky Blue 6B

    		 Amyloid-β NF-κB Inflammation/Immunology
    Direct Blue 1 (Chicago Sky Blue 6B) is a complex dye for background autofluorescence in immunofluorescence histochemistry. Direct Blue 1 is a potent and competitive VGLUT inhibitor. Direct Blue 1 can inhibit the Aβ-binding small molecule PrP ligand. Direct Blue 1 has anti-inflammatory activity [6].
    Direct Blue 1
  • HY-117427
    D5D-IN-326
    1 Publications Verification

    		 Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice .
    D5D-IN-326
  • HY-122615B
    SPOP-IN-6b dihydrochloride
    1 Publications Verification

    		 E1/E2/E3 Enzyme Cancer
    SPOP-IN-6b dihydrochloride is a potent speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM .
    SPOP-IN-6b dihydrochloride
  • HY-160025
    IDO antagonist-1

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO antagonist-1 (compound 163) is an antagonist of IDO . IDO antagonist-1 inhibits pancreatic adenocarcinoma cells growth in C57BL/6 mice .
    IDO antagonist-1
  • HY-128435
    2,4'-Dihydroxybenzophenone-1

    		Estrogen Receptor/ERR Metabolic Disease
    2,4'-Dihydroxybenzophenone ((Z)-SU4312) exhibited estrogenic activities. 2,4'-Dihydroxybenzophenone has oral bioactivity that can effectively protect C57BL/6J mice from Acetaminophen (HY-66005, APAP)-induced hepatotoxicity .
    2,4'-Dihydroxybenzophenone-1
  • HY-169953
    BT-Amide

    		Pyk2 Metabolic Disease
    BT-Amide is the orally active inhibitor for Pyk2 kinase with IC50 of 44.69 nM. BT-Amide prevents glucocorticoid-induced bone loss, exhibits bone protective activity in C57BL/6 mouse .
    BT-Amide
  • HY-157429
    25N-N1-Nap

    		5-HT Receptor Neurological Disease
    25N-N1-Nap (compound 16) is a β-arrestin-biased 5-HT2A agonist. 25N-N1-Nap antagonizes phencyclidine induced hyperactivity in Male C57BL/6 J mice .
    25N-N1-Nap
  • HY-144743
    ATX inhibitor 12

    		Phosphodiesterase (PDE) Others
    ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC50 of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .
    ATX inhibitor 12
  • HY-D1056A5
    Lipopolysaccharides, from E. coli K-235

    LPS, from Escherichia coli (K-235)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from E. coli (Escherichia coli) K-235 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli K-235 exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A). Lipopolysaccharides, from E. coli K-235 have a mitogenic effect on C57BL/10ScN spleen cells. Additionally, LPS purified using butanol and deoxycholic acid methods stimulates spleen cells in C57BL/10ScCR and C3H/HeJ mice .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from E. coli K-235
  • HY-122615A
    SPOP-IN-6b hydrochloride

    		E1/E2/E3 Enzyme Cancer
    SPOP-IN-6b hydrochloride is a potent speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM .
    SPOP-IN-6b hydrochloride
  • HY-W740175
    6b-Hydroxy triamcinolone acetonide

    		Glucocorticoid Receptor Inflammation/Immunology
    6b-Hydroxy triamcinolone acetonide is a metabolite of the synthetic corticosteroid Triamcinolone acetonide (HY-B0636). 6b-Hydroxy triamcinolone acetonide is formed from triamcinolone acetonide by the cytochrome P450 (CYP) isoforms CYP3A4, CYP3A5, and CYP3A7.
    6b-Hydroxy triamcinolone acetonide
  • HY-122615
    SPOP-IN-6b
    1 Publications Verification

    		 E1/E2/E3 Enzyme Cancer
    SPOP-IN-6b is a speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM (patent CN 107141287, SPOP-B-88) .
    SPOP-IN-6b
  • HY-172930
    PVTX-405

    		Molecular Glues IKZF Family Potassium Channel Inflammation/Immunology Cancer
    PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC50  of  0.7 nM and a Dmax of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC50 of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn 391V C57BL/6 mice .
    PVTX-405
  • HY-170362
    cGAS-IN-4

    		Cyclic GMP-AMP Synthase Inflammation/Immunology
    cGAS-IN-4 (Compound 36) is an orally active inhibitor for cyclic GMP-AMP synthase (cGAS) with IC50 of 32 nM and 5.8 nM for h-cGAS and m-cGAS. cGAS-IN-4 inhibits the cGAMP in THP-1 cell with an IC50 of 60 nM, which improves the cellular potency. cGAS-IN-4 exhibits anti-inflammatory efficacy in Concanavalin A (HY-P2149)-induced acute liver injury in mouse models . orally active, THP-1, C57Bl/6 mouse, orally active
    cGAS-IN-4
  • HY-N0538
    Xylitol

    Xylite

    		 Autophagy Endogenous Metabolite Bacterial Atg7 Atg8/LC3 Metabolic Disease Cancer
    Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model .
    Xylitol
  • HY-168081
    PD-1/PD-L1-IN-52

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-52 (Compound III-5) is an orally active PD-1/PD-L1 inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC50 of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .
    PD-1/PD-L1-IN-52
  • HY-162972
    PROTAC PD-L1 degrader-2

    		PROTACs PD-1/PD-L1 Cancer
    PROTAC PD-L1 degrader-2 (Compound 9i) is a PROTAC degrader for PD-L1, that inhibits PD-L1 with an IC50 of 197.4 nM and exhibits an affinity with PD-L1 with a Kd of 301 nM. PROTAC PD-L1 degrader-2 promotes the internalization of PD-L1 on the cell membrane, and induces PD-L1 degradation via the synergistic effect of the proteasome and lysosomal pathways. PROTAC PD-L1 degrader-2 can activate the immune system, and exhibits antitumor efficacy in MC38 C57BL/6 mouse model .
    PROTAC PD-L1 degrader-2
  • HY-176533
    S1PR5-IN-1

    		LPL Receptor Neurological Disease
    S1PR5-IN-1 (Compound 7a) is a selective and BBB-penetrable S1PR5 inhibitor with an IC50 of 85.4 nM. S1PR5-IN-1 has a superior binding capacity on S1PR5 with Kds of 2.2, 4.6, and 27.6 nM for recombinant human S1PR5 cell membranes, C57BL/6 mouse brain, and human cerebral cortex, respectively. S1PR5-IN-1 can be used for neurodegenerative disorders like multiple sclerosis research .
    S1PR5-IN-1
  • HY-W768347
    Xylitol-13C5

    Xylite-13C5

    		 Isotope-Labeled Compounds Bacterial Autophagy Endogenous Metabolite Atg8/LC3 Atg7 Cancer
    Xylitol- 13C5 (Xylite- 13C5) is the 13C-labeled Xylitol (HY-N0538). Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model .
    Xylitol-13C5
  • HY-147663
    hCAIX-IN-6

    		Carbonic Anhydrase Cancer
    Compounds 6b and 14g showed significant inhibitory effect on tumor related subtype HCA IX with low nanomolar potency, while 6k was effective on HCA XII. Compounds 6b, 14g and 6k can be considered as the leading molecules for the development of future cancer therapeutic drugs based on new mechanisms of action.
    hCAIX-IN-6
  • HY-W727144
    2-Heptyl-4,6-dihydroxybenzoic acid

    		Endogenous Metabolite Others
    2-Heptyl-4,6-dihydroxybenzoic acid (compound 6b) is a known component of orcinol .
    2-Heptyl-4,6-dihydroxybenzoic acid
  • HY-145897
    NMDA-IN-2

    		iGluR Neurological Disease
    NMDA-IN-2 (compound 6b), a Procaine derivative, is a NMDA receptor 2B subtype inhibitor .
    NMDA-IN-2
  • HY-14690B
    rel-Ecopipam hydrobromide

    rel-SCH 39166 hydrobromide

    		 Dopamine Receptor Neurological Disease
    rel-Ecopipam (rel-SCH 39166) (Compound 6b) hydrobromide is a D1 receptor antagonist (Ki: 1.30 nM) .
    rel-Ecopipam hydrobromide
  • HY-W739851
    6β-Hydroxytestosterone-d3

    		Isotope-Labeled Compounds Others
    6b-Hydroxy Testosterone-d3 is the deuterium labeled 6β-Hydroxytestosterone (HY-141626).
    6β-Hydroxytestosterone-d3
  • HY-126117
    (+)-Xylariamide A

    		Fungal Carbonic Anhydrase Infection
    (+)-Xylariamide A (compound 6b) is a mycobacterial and fungal carbonic anhydrase probe with inhibitory activity against pathogen β-carbonic anhydrases .
    (+)-Xylariamide A
  • HY-155057
    SARS-CoV-2 Mpro-IN-8

    		SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-8 (compound 6b) is an antiviral agent with anti-SARS-CoV-2 properties .
    SARS-CoV-2 Mpro-IN-8
  • HY-W741607
    6β-Hydroxy norethindrone acetate-d3

    		Isotope-Labeled Compounds Others
    6β-Hydroxy norethindrone acetate-d3 is the deuterium labeled 6b-Hydroxy Norethindrone Acetate (HY-W741606).
    6β-Hydroxy norethindrone acetate-d3
  • HY-162909
    Tyrosinase-IN-38

    		Tyrosinase Metabolic Disease
    Tyrosinase-IN-38 (compound 6b) is a competitive Tyrosinase inhibitor with IC50 value of 25.82 μM. Tyrosinase-IN-38 has antioxidant activity .
    Tyrosinase-IN-38
  • HY-W171983
    Notum-IN-1

    		Wnt Cancer
    Notum-IN-1 (compound 6b) is an orally active, selective and brain penetrant inhibitor of Notum. Notum-IN-1 blocks the Wnt signaling in vivo in mouse .
    Notum-IN-1
  • HY-156414
    DHFR-IN-11

    		Dihydrofolate reductase (DHFR) Infection
    DHFR-IN-11 (compound 6b) is inhibitor of DHFR, and has inhibitory potency versus M. tuberculosis DHFR enzyme with IC50 values 5.70 μM .
    DHFR-IN-11
  • HY-147662
    hCAIX-IN-5

    		Carbonic Anhydrase Cancer
    hCAIX-IN-5 (compound 6b) is a potent and selective hCAIX inhibitor with KIs of >10000, >10000, 130.7, 829.1 nM for hCAI, hCAII, hCAIV, hCAIX, respectively .
    hCAIX-IN-5
  • HY-163397
    Antibacterial agent 196

    		Fungal Infection
    Antibacterial agent 196 (compound 6b) is a coumarin derivative containing oxime ether structure, and shows antifungal activity, with the EC50 of 0.46 μg/mL against Rhizoctonia solani .
    Antibacterial agent 196
  • HY-123707
    KPU-300

    		Microtubule/Tubulin Cancer
    KPU-300 (compound 6b) is a tubulin inhibitor. KPU-300 has potent cytotoxicity with an IC50 value of 7.0 nM against HT-29 cells .
    KPU-300
  • HY-144383
    RXR antagonist 2

    		RAR/RXR Others
    RXR antagonist 2 (compound 6b) is a potent antagonist of RXR with a Ki and Kd of 0.391 and 0.281 μM. RXR antagonist 2 has the potential for the research of RXR related diseases .
    RXR antagonist 2
  • HY-173309
    P53/TLR2 modulator-1

    		MDM-2/p53 Toll-like Receptor (TLR) Apoptosis MyD88 Bcl-2 Family Interleukin Related Cancer
    P53/TLR2 modulator-1 (Compound Z9) is a modulator that targets both the P53 pathway and TLR2 simultaneously, exhibiting anti-radiation activity. P53/TLR2 modulator-1 reduces apoptosis by inhibiting the radiation-induced expression of P53 and Bax. At the same time, it activates the TLR2 pathway, upregulates the expression of downstream proteins MyD88 and P65, and promotes the secretion of cytokines such as IL-6, thus exerting an anti-radiation effect. P53/TLR2 modulator-1 shows significant anti-radiation activity against both AHH-1 cells and HUVECs. It can also increase the survival rate of C57BL/6J mice irradiated with a lethal dose of radiation and reduce the damage to their hematopoietic system, the villous structure of the small intestine, and the spleen caused by radiation. P53/TLR2 modulator-1 can be used in the research of radiation injury-related diseases .
    P53/TLR2 modulator-1
  • HY-161475
    Luciferase-IN-4

    		Reactive Oxygen Species (ROS) Others
    Luciferase-IN-4 (Compound 6b) is an inhibitor for luciferase with IC50 of 4.1 μM. Luciferase-IN-4 inhibits purified luciferase in P. pyralis with IC50 of 2.0 μM .
    Luciferase-IN-4
  • HY-130716
    Thalidomide-NH-C10-COOH

    		E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis Cancer
    Thalidomide-NH-C10-COOH (compound 6b) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and a linker used in PROTAC technology .
    Thalidomide-NH-C10-COOH
  • HY-102090
    B7/CD28 interaction inhibitor 1

    		CD28 Inflammation/Immunology
    B7/CD28 interaction inhibitor 1 (copmound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC50 of 50 nM .
    B7/CD28 interaction inhibitor 1
  • HY-N10906
    (4R,4aS,5aS,6aR,6bS,7aR)-4-Hydroxy-3,6b-dimethyl-5-methylene-4,4a,5,5a,6,6a,7,7a-octahydrocyclopropa[2,3]indeno[5,6-b]furan-2(6bH)-one

    		Others Others
    (4R,4aS,5aS,6aR,6bS,7aR)-4-Hydroxy-3,6b-dimethyl-5-methylene-4,4a,5,5a,6,6a,7,7a-octahydrocyclopropa[2,3]indeno[5,6-b]furan-2(6bH)-one is a sesquiterpene lactone .
    (4R,4aS,5aS,6aR,6bS,7aR)-4-Hydroxy-3,6b-dimethyl-5-methylene-4,4a,5,5a,6,6a,7,7a-octahydrocyclopropa[2,3]indeno[5,6-b]furan-2(6bH)-one
  • HY-151143
    α-Glucosidase-IN-19

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-19 (Compound 6B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.63 μM. α-Glucosidase-IN-19 shows anti-diabetic activity .
    α-Glucosidase-IN-19
  • HY-158262
    Bradykinin B1 receptor antagonist 1

    		Bradykinin Receptor Neurological Disease
    Bradykinin B1 receptor antagonist 1 (compound 6B) is a potent and cross the blood-brain barrier bradykinin B1 antagonist. Bradykinin B1 receptor antagonist 1 has the potential for the research of pain .
    Bradykinin B1 receptor antagonist 1
  • HY-169010
    Pomalidomide-CO-C5-Br

    		E3 Ligase Ligand-Linker Conjugates Infection
    Pomalidomide-CO-C5-Br (Compound 6b) is a conjugated compound of the E3 ligand Pomalidomide and linker. It can be used to synthesize highly effective PROTAC molecules targeting ADC (HY-169008) .
    Pomalidomide-CO-C5-Br
  • HY-141411
    (Rac)-Zevaquenabant

    (Rac)-MRI-1867

    		 Cannabinoid Receptor NO Synthase Others
    (Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB1R)/iNOS antagonist, with a Ki of 5.7 nM for CB1R. (Rac)-Zevaquenabant is potential for the research of liver fibrosis .
    (Rac)-Zevaquenabant
  • HY-163111
    Antibacterial agent 170

    		Bacterial Infection
    Antibacterial agent 170 (compound 6b) is a potent antibacterial agent which inhibits the formation of P. aeruginosa PAO1 biofilm. Antibacterial agent 170 exhibits quorum sensing inhibitor effect by the las system. Antibacterial agent 170 can used in study microbial resistance .
    Antibacterial agent 170
  • HY-149803
    S1R agonist 1

    		Sigma Receptor Neurological Disease
    S1R agonist 1 (Compound 6b) is a selective S1R agonist with Kis of 0.93 nM and 72 nM for S1R and S2R, respectively. S1R agonist 1 exhibits neuroprotection against ROS and NMDA-induced neurotoxicity .
    S1R agonist 1
  • HY-149803A
    S1R agonist 1 hydrochloride

    		Sigma Receptor Neurological Disease
    S1R agonist 1 (Compound 6b) hydrochloride is a selective S1R agonist with Kis of 0.93 nM and 72 nM for S1R and S2R, respectively. S1R agonist 1 hydrochloride exhibits neuroprotection against ROS and NMDA-induced neurotoxicity .
    S1R agonist 1 hydrochloride
  • HY-158181
    A3AR agonist 5

    		Adenosine Receptor Inflammation/Immunology
    A3AR agonist 5 (Compound 6b) is a A3 adenosine receptor (A3AR) activator, with EC50 and Ki values of 0.14 nM and 6.36 nM for cAMP and hA3, respectively. A3AR agonist 5 can be used in pain and inflammatory research .
    A3AR agonist 5
  • HY-170487
    MAO-B-IN-38

    		Monoamine Oxidase Neurological Disease
    MAO-B-IN-38 (Compound 6b) is a reversible and competitive MAO-B inhibitor, with IC50 values of 0.03 and 21.46 µM for MAO-B and MAO-A, respectively. MAO-B-IN-38 can be used for the research of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases .
    MAO-B-IN-38
  • HY-156113
    RET-IN-25

    		RET Cancer
    RET-IN-25 (compound 6b) is a RET kinase inhibitor with anticancer activity. RET-IN-25 inhibits medullary thyroid carcinoma (MTC) with IC50s of 3.6 μM (3 days) and 3.0 μM (6 days) against TT(C634R) MTC .
    RET-IN-25

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: